首页> 外文期刊>The Lancet >Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)
【24h】

Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)

机译:中国高血压的患病率,意识,治疗和控制:基于人口的筛查研究中的1·700万人的数据(中国和平百万人项目)

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Background Hypertension is common in China and its prevalence is rising, yet it remains inadequately controlled. Few studies have the capacity to characterise the epidemiology and management of hypertension across many heterogeneous subgroups. We did a study of the prevalence, awareness, treatment, and control of hypertension in China and assessed their variations across many subpopulations. Methods We made use of data generated in the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project from Sept 15, 2014, to June 20, 2017, a population-based screening project that enrolled around 1·7 million community-dwelling adults aged 35–75 years from all 31 provinces in mainland China. In this population, we defined hypertension as systolic blood pressure of at least 140 mm Hg, or diastolic blood pressure of at least 90 mm Hg, or self-reported antihypertensive medication use in the previous 2 weeks. Hypertension awareness, treatment, and control were defined, respectively, among hypertensive adults as a self-reported diagnosis of hypertension, current use of antihypertensive medication, and blood pressure of less than 140/90 mm Hg. We assessed awareness, treatment, and control in 264?475 population subgroups—defined a priori by all possible combinations of 11 demographic and clinical factors (age [35–44, 45–54, 55–64, and 65–75 years], sex [men and women], geographical region [western, central, and eastern China], urbanity [urban vs rural], ethnic origin [Han and non-Han], occupation [farmer and non-farmer], annual household income [ Findings The sample contained 1?738?886 participants with a mean age of 55·6 years (SD 9·7), 59·5% of whom were women. 44·7% (95% CI 44·6–44·8) of the sample had hypertension, of whom 44·7% (44·6–44·8) were aware of their diagnosis, 30·1% (30·0–30·2) were taking prescribed antihypertensive medications, and 7·2% (7·1–7·2) had achieved control. The age-standardised and sex-standardised rates of hypertension prevalence, awareness, treatment, and control were 37·2% (37·1–37·3), 36·0% (35·8–36·2), 22·9% (22·7–23·0), and 5·7% (5·6–5·7), respectively. The most commonly used medication class was calcium-channel blockers (55·2%, 55·0–55·4). Among individuals whose hypertension was treated but not controlled, 81·5% (81·3–81·6) were using only one medication. The proportion of participants who were aware of their hypertension and were receiving treatment varied significantly across subpopulations; lower likelihoods of awareness and treatment were associated with male sex, younger age, lower income, and an absence of previous cardiovascular events, diabetes, obesity, or alcohol use (all p Interpretation Among Chinese adults aged 35–75 years, nearly half have hypertension, fewer than a third are being treated, and fewer than one in twelve are in control of their blood pressure. The low number of people in control is ubiquitous in all subgroups of the Chinese population and warrants broad-based, global strategy, such as greater efforts in prevention, as well as better screening and more effective and affordable treatment. Funding Ministry of Finance and National Health and Family Planning Commission, China.
机译:发明内容背景高血压在中国很常见,其普遍存在较高,但它仍然不充分控制。很少有研究能够在许多异质亚组中表征血液流血和高血压管理的能力。我们研究了中国高血压的患病率,意识,治疗和控制,并评估了许多群体的变化。方法我们在2014年9月15日至2017年6月15日至2017年6月20日至2017年6月20日,截至2017年6月20日,以2017年6月20日举办了一项基于人口的筛查项目,这些方法采用了一项基于人口的筛查项目,该项目纳入了大约1·700万个社区 - 从中​​国大陆所有31个省份的35-75岁的成年人。在该群群中,我们将高血压定义为收缩压至少140 mm Hg,或舒张压血压至少为90mm Hg,或在过去的2周内使用自我报告的抗高血压药物。分别定义高血压意识,治疗和对照,分别是一种高血压成人作为高血压诊断,目前使用抗高血压药物,血压小于140/90mm Hg。我们评估了264年的意识,治疗和控制?475个人口亚群定义了11个人口统计和临床因素的所有可能组合(年龄[35-44,45-54,55-65岁],性别[男女],地理区域[中国,中部和东部,中国东部],城市[城市与农村],族裔血统[汉族,非农],占领[农民和非农],年庭家庭收入[调查结果该样本含有1?738?886名参与者的平均年龄为55·6岁(SD 9·7),59·5%是妇女。44·7%(95%CI 44·6-44·8)样品的高血压,其中44·7%(44·6-44·8)意识到其诊断,30·1%(30·0-30·2)正在进行规定的抗高血压药物,7·2 %(7·1-7·2)达到了控制。年龄标准化和性标准化的高血压患病率,意识,治疗和对照率为37·2%(37·1-37·3),36· 0%(35·8-36·2),22·9%(22·7-23·0),分别为5·7%(5·6-5·7)。最常用的药物类钙通道阻滞剂(55·2%,55·0-55·4)。在治疗高血压但未控制的个体中,81·5%(81·3-81·6)只使用一种药物。意识到其高血压和接受治疗的参与者的比例在群体中显着变化;较低的意识和治疗的可能性与男性性交,更年轻,收入较低,并且缺乏先前的心血管事件,糖尿病,肥胖或酒精使用(所有35-75岁的中国成年人的P解释,近一半的高血压,少于三分之一被治疗,并且十二分之比较少,控制着他们的血压。控制中的少数人在中国人口的所有亚组中都是无处不在的,并认证基于广泛的全球战略,如更加努力的预防,以及更好的筛选和更有效,更实惠的治疗。资助财政部和国家卫生和计划生育委员会,中国。

著录项

  • 来源
    《The Lancet》 |2017年第10112期|共10页
  • 作者单位

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

    Center for Outcomes Research and Evaluation Yale University/Yale-New Haven Hospital;

    Department of Biostatistics;

    Department of Biostatistics;

    Center for Outcomes Research and Evaluation Yale University/Yale-New Haven Hospital;

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

    Department of Mathematics;

    Center for Outcomes Research and Evaluation Yale University/Yale-New Haven Hospital;

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

    Department of Biostatistics;

    Center for Outcomes Research and Evaluation Yale University/Yale-New Haven Hospital;

    Health Outcomes Research Saint Luke's Mid America Heart Institute/University of Missouri-Kansas;

    Division of Cardiology University of Colorado Anschutz Medical Campus;

    Center for Outcomes Research and Evaluation Yale University/Yale-New Haven Hospital;

    National Clinical Research Center of Cardiovascular Diseases State Key Laboratory of;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号